Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- Japan Launches Fall COVID-19 Vaccination Campaign
September 21, 2023
- Apply Brand-Based Price Revisions to Qualified Generic Makers: JGA
September 21, 2023
- JPWA Urges Price Hikes for Drugs with NHI Tag Below 20 Yen
September 21, 2023
- MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
- 10-20% of Infected Adults Suffer Long COVID: MHLW Study
September 20, 2023
- Japan to End Use of Original COVID Vaccine, Previous Omicron Jabs
September 20, 2023
- Hamachi, Miyazaki Named Senior Vice Health Ministers
September 19, 2023
- Health Minister Set to Visit Boston Life Sciences Cluster
September 19, 2023
- Opposition Party Leader Raps Takemi’s Appointment as Health Minister
September 19, 2023
- Japan Grants Orphan Tag to Tafinlar/Mekinist, Retevmo
September 19, 2023
- Japan to Require Out-of-Pocket Cost for COVID Drugs from October
September 19, 2023
- New Health Minister Vows to Put Public Needs First in 2024 Drug Pricing Reform
September 15, 2023
- Japan to Basically Drop Japanese PI Requirement before Global Clinical Trials
September 14, 2023
- Chuikyo Mixed on Expanding Range of CEA Price Adjustments for Pricey Meds
September 14, 2023
- Bimzelx, Pivlaz Escape Price Cuts after Cost-Effectiveness Assessments
September 14, 2023
- Keizo Takemi Tapped as New Health Minister in Cabinet Reshuffle
September 14, 2023
- MHLW Must Take Big Step on Drug Lags, Losses in FY2024 Reform: Official
September 13, 2023
- University Hospital Reform Report Finds Inadequate Review of High-Price Drug Use
September 13, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…